Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 12 2021 - 7:57AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of March, 2021
Commission
File Number: 001-36582
Auris
Medical Holding Ltd.
(Exact
name of registrant as specified in its charter)
Clarendon
House, 2 Church Street
Hamilton
HM 11, Bermuda
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes
☐ No ☒
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes
☐ No ☒
Notice
of Warrant Exercise and Loan Conversion
Auris
Medical Holding Ltd. (NASDAQ: EARS, the “Company”) today announced that on March 9, 2021 one investor in the May 2019
financing of common shares and warrants (the “May 2019 Offering”) exercised warrants for 897,435 common shares at
the exercise price of CHF 4.34 per share, for net proceeds of approximately USD 4.2 million. Together with the previously announced
exercises by other investors in the May 2019 Offering in December 2020 for 1,263,845 common shares, all warrants issued through
the May 2019 Offering have been exercised by now.
In
addition, the Company announced that FiveT Capital Holding Ltd. (“FiveT”) converted on March 4, 2021 the remaining
principal amount and accrued interest of a convertible loan to its affiliate Altamira Medica Ltd. into common shares of Medical
Holding Ltd. at the maximum conversion price of USD 1.35 per share. The loan of CHF 1.5 m had been disbursed on September 8, 2021
with a duration of 18 months and carried an interest rate of 8% p.a.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Auris
Medical Holding Ltd.
|
|
|
|
By:
|
/s/
Thomas Meyer
|
|
|
Name:
|
Thomas
Meyer
|
|
|
Title:
|
Chief
Executive Officer
|
Date:
March 12, 2021
2
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Apr 2024 to May 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From May 2023 to May 2024